| | 179324-69-7 Basic information More.. |
| Product Name: | Bortezomib | | Synonyms: | Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu;MG-341 PS-341;BortezoMib Base;bortezoMib(other);MLM341;BortezoMib R;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]- | | CAS: | 179324-69-7 | | MF: | C19H25BN4O4 | | MW: | 384.24 | | EINECS: | 605-854-3 | | Mol File: | 179324-69-7.mol |  |
Use
Bortezomib belong to the class of drugs called proteasome inhibitors and is licensed in the United States and
the United Kingdom for the treatment of multiple myeloma. The drug has been licensed for patients in whom
the myeloma has progressed despite prior treatment or where a bone marrow transplant is not possible or was
not successful. It is marketed under the name Velcade? or Cytomib?. Velcade is administered via injection
and is sold as powder for reconstitution.
Bortezomib was the first drug approved in the new drug class of proteasome inhibitors and boron seems to
be its active element. For the mode of action, it is believed that the boron atom binds with high affinity and
specificity to the catalytic site of 26S proteasome and inhibits its action. Therapy with Bortezomib can lead
to a variety of adverse reactions, including peripheral neuropathy, myelosuppression, renal impairment and
gastrointestinal (GI) disturbances together with changes in taste. Nevertheless, the side effects are in most
cases less severe than with alternative treatment options such as bone marrow transplantation.
- Bortezomib
-
- US $0.00 / kg
- 2024-04-12
- CAS:179324-69-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
- Bortezomib
-
- US $0.00 / KG
- 2024-03-16
- CAS:179324-69-7
- Min. Order: 100g
- Purity: 98%+
- Supply Ability: 100kg
- Bortezomib
-
- US $0.00-0.00 / g
- 2023-11-01
- CAS:179324-69-7
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100kgs/month
|
|
179324-69-7
Recommend Suppliers |
|